Perforin and Fas/Fas ligand-mediated cytotoxicity in acute and chronic woodchuck viral hepatitis

Clinical and Experimental Immunology

Volumn 118, Issue 1, 1999, Pages 63-70

  Hodgson, P D ^a   Grant, M D ^b,c   Michalak, Tomasz I ^a,c  

^a Division of Basic Medical Sciences   (Canada)

^b Immunology Program   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cytotoxicity; Fas; Perforin; Viral hepatitis; Woodchuck hepatitis virus

Indexed keywords

FAS ANTIGEN; PERFORIN;

ANIMAL CELL; ARTICLE; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNE RESPONSE; LIGAND BINDING; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIRUS HEPATITIS; WOODCHUCK;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; K562 CELLS; LEUKOCYTES, MONONUCLEAR; MALE; MARMOTA; MEMBRANE GLYCOPROTEINS; MICE; PHYTOHEMAGGLUTININS; PORE FORMING CYTOTOXIC PROTEINS; TIME FACTORS;

EID: 0032869698     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01010.x     Document Type: Article

References (34)

1. 1 Summers J. Three recently described animal virus models for human hepatitis B virus. Hepatology 1981; 1:179-83.
2. 2 Michalak TI. The woodchuck animal model of hepatitis B. Viral Hepatitis Rev 1998; 4:139-65.
3. 3 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13:29-60.
4. 4 Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047-58.
5. 5 Ferrari C, Penna A, Bertoletti A et al. Cellular and immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:3442-9.
6. 6 Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97:1655-65.
7. 7 Ando K, Moriyama T, Guidotti LG et al. Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178:1541-54.
8. 8 Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806-9.
9. 9 Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182:1223-30.
10. 10 Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of Fas ligand in development of hepatitis. Nat Med 1997; 3:409-13.
11. 11 Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158:5692-7.
12. 12 Kagi D, Lederman B, Burki K et al. Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired in perforin deficient mice. Nature 1994; 369:31-37.
13. 13 Michalak TI, Lin B. Molecular species of hepadnavirus core and envelope polypeptides in hepatocyte plasma membrane of woodchucks with acute and chronic viral hepatitis. Hepatology 1994; 20:275-86.
14. 14 Michalak TI, Pardoe IU, Coffin CS et al. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999; 29:928-38.
15. 15 Pardoe IU, Michalak TI. Detections of hepatitis B and woodchuck hepatitis viral DNA in plasma and mononuclear cells from heparinized blood by polymerase chain reaction. J Virol Methods 1995:51:277-88.
16. 16 Michalak TI, Snyder RL, Churchill ND. Characterization of the incorporation of woodchuck hepatitis virus surface antigen into hepatocyte plasma membrane in woodchuck hepatitis and in the virus-induced hepatocellular carcinoma. Hepatology 1989; 10:44-55.
17. 17 Michalak TI, Lin B, Churchill ND, Dzwonkowski P, Desousa JRB. Hepadna virus nucleocapsid and surface antigens and the antigen-specific antibodies associated with hepatocyte plasma membranes in experimental woodchuck acute hepatitis. Lab Invest 1990; 62:680-9.
18. 18 De Leon M, Jackson KM, Cavanaugh JR, Mbangkollo D, Verret CR. Arrest of the cell-cycle reduces susceptibility of target-cells to perforin mediated lysis. J Cell Biochem 1998; 69:425-35.
19. 19 Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and specific specificity. Int Immunol 1994; 6:1567-74.
20. 20 Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995; 166:236-46.
21. 21 Michalak TI, Churchill ND, Codner D, Drover S, Marchall WH. Identification of woodchuck class I MHC antigens using monoclonal antibodies. Tissue Antigens 1995; 45:333-42.
22. 22 Kuwano K, Arai S. Involvement of two distinct killing mechanisms in bystander target cell lysis induced by a cytotoxic T lymphocyte clone. Cell Immunol 1996; 169:288-93.
23. 23 Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO 1995; 14:1129-35.
24. 24 Smyth MJ, Sutton VR, Kershaw MH, Trapani JA. Xenospecific cytotoxic T lymphocytes use perforin and Fas mediated pathways. Transplantation 1996; 62:1529-32.
25. 25 Sayers TJ, Brooks AD, Lee J-Ket al. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol 1998; 161:3957-65.
26. 26 See DM, Khemka P, Sahl L, Bui T, Tilles JG. The role of natural killer cells in viral infection. Scand J Immunol 1997; 46:217-24.
27. 27 Smyth MJ, Trapani JA. The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology. J Virol 1998; 72:1-9.
28. 28 Chemello L, Bortolotti MF, Schiavon E et al. Natural killer activity in patients with acute viral hepatitis. Clin Exp Immunol 1986; 64:59-64.
29. 29 Echevarria S, Casafont F, Micra M et al. Interleukin-2 and natural killer activity in acute type B hepatitis. Hepato-Gastroenterol 1991; 38:307-10.
30. 30 Actis GC, Ponzzetto A, D'Urso N et al. Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. Liver 1991; 11:106-13.
31. 31 Ono K, Yamanaga Y, Yamamoto K, Koga SI, Nishimura J, Nawata H. Natural killing activities in chronic liver diseases and hepatocellular carcinoma. J Clin Immunol 1996; 16:41-45.
32. 32 De Martino M, Rossi ME, Muccioli AT, Resti M, Vierucci A. Interference of hepatitis B surface antigen with natural killer cell function. Clin Exp Immunol 1985; 61:90-95.
33. 33 Azzari C, Rossi ME, Resti Met al. VIP restores natural killer cell activity depressed by hepatitis B surface antigen. Viral Immunol 1992; 5:195-200.
34. 34 Brutkiewicz RR, Welsh RM. Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J Virol 1995; 69:3967-71.